Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
US Army
McKinsey
Fish and Richardson
UBS
Fuji
Mallinckrodt
Queensland Health
Novartis

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,393,256

« Back to Dashboard

Which drugs does patent 9,393,256 protect, and when does it expire?

Patent 9,393,256 protects HARVONI and is included in one NDA.

This patent has seventy patent family members in twenty-seven countries.
Summary for Patent: 9,393,256
Title:Methods for treating HCV
Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.
Inventor(s): Ray; Adrian S. (Burlingame, CA), Link; John O. (San Francisco, CA), Oldach; David W. (Chapel Hill, NC), Delaney, IV; William E. (Foster City, CA), Mo; Hongmei (Palo Alto, CA), Yang; Cheng Yong (Foster City, CA)
Assignee: Gilead Pharmasset LLC (Foster City, CA)
Application Number:13/875,252
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 9,393,256

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up FOR THE TREATMENT OF HEPATITIS C ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,393,256

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,889,159 Compositions and methods for treating hepatitis C virus ➤ Sign Up
9,549,941 Compositions and methods for treating hepatitis C virus ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,393,256

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Morocco 20150030 ➤ Sign Up
South Korea 20140096029 ➤ Sign Up
South Korea 101560994 ➤ Sign Up
South Korea 20140108645 ➤ Sign Up
Japan 2016053096 ➤ Sign Up
Japan 2014532657 ➤ Sign Up
Japan 6220994 ➤ Sign Up
Japan 2017057230 ➤ Sign Up
Japan 6073897 ➤ Sign Up
Japan 5899327 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Argus Health
US Army
Express Scripts
McKesson
Accenture
QuintilesIMS
Queensland Health
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot